Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Melina PeressiniMaría Del Rosario García-CampeloBartomeu MassutiCristina MartíManuel CoboVanesa GutiérrezManuel DómineJose FuentesMargarita Majem TarruellaJavier De Castro CarpeñoJuan Felipe CordobaMaria Pilar DizDolores IslaEmilio EstebanEnric CarcerenyLaia VilaAlberto Moreno-VegaSilverio RosAmaia MorenoFrancisco Javier GarciaGerardo HuidobroCarlos AguadoVictor Cebey-LopezJavier ValdiviaRamon PalmeroPilar LianesMarta López-Brea PiquerasOscar Juan VidalMariano Provencio PullaEdurne ArriolaJavier BaenaMercedes Herrera-JuárezHelena BoteMagdalena MoleroVera AdradasSantiago Ponce-AixÁngel Nuñez-BuizaÁlvaro C UceroSusana HernandezFernando López-RíosEsther CondeLuis G Paz-AresJon ZugazagoitiaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Preexisting IFNγ-driven immunity and mitochondrial metabolism seem to be correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.